第54届美国血液学会年会急性淋巴细胞白血病研究领域的主要进展报道

Report on main progress of acute lymphoblastic leukemia in the 54th ASH annual meeting

急性淋巴细胞白血病（ALL）是一组异质性疾病，其预后与患者年龄、免疫亚型、基因和分子生物学特征密切相关。第54届美国血液学会（ASH）年会大量报道了有关ALL发病机制、预后及治疗等领域的最新进展。对ALL的基因表达谱、靶向治疗及造血干细胞移植等方面的亮点进行介绍。

Acute lymphoblastic leukemia （ALL） is a heterogeneous disease affected by patient＂ s age, immunologic subtype, genetic and molecular features. In the 54th ASH annual meeting, lots of new discoveries about the biology, prognosis and treatment of ALL were reported. Here highlights of genomic profiling, new targeted therapy and hematopoietic stenl cell transplantation for ALL presented in this meeting are introduced. [